Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia (ECP-012) (ECP-012)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01629927 |
Recruitment Status :
Completed
First Posted : June 28, 2012
Last Update Posted : June 28, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
X-linked Hypohidrotic Ectodermal Dysplasia Hypohidrotic Ectodermal Dysplasia |
Study Type : | Observational |
Actual Enrollment : | 30 participants |
Official Title: | Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia (ECP-012) |
Study Start Date : | March 2012 |
Actual Primary Completion Date : | April 2012 |
Actual Study Completion Date : | June 2012 |

Group/Cohort |
---|
HED-affected males
Male subjects affected by HED
|
Male controls
Male subjects not affected by HED
|
- Collecting demographic and clinical status information in XLHED affected males and unaffected male siblings using a medical questionnaire and clinical photographs [ Time Frame: Study day 1 - Day of study conduct ]
- Assess the feasibility of developing a non-invasive newborn screening tool, which will enable detection of clinical symptoms of HED/XLHED at birth, based on an analysis of a two dimensional photograph [ Time Frame: Study day 1 - Day of study conduct ]
- The secondary objective of this descriptive study is to use skin assessment techniques to characterize skin properties in male subjects affected by XLHED compared with unaffected male sibling controls, including determination of the number of sweat ducts [ Time Frame: Study day 1 - Day of study conduct ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Year and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
Subjects must meet all of the following criteria to be enrolled in this study.
- Attending the 2012 Spanish Association for those Affected by Ectodermal Dysplasia Annual Reunion;
- One year of age or greater;
-
Conform to one of the following requirements for providing informed consent/assent:
- If more than 18 years of age, subjects must provide signed informed consent;
- If less than 18 years of age and it is determined that the subject is capable of providing assent, both the assent of the subject and consent of the parent(s) or guardian of that subject must be granted. Under this condition, both parents of the subject should give their permission, unless 1 parent is deceased, unknown, incompetent, or not available;
- If the subject is incapable of providing assent, the consent of the parent(s) or guardian of the subject must be granted. Under this condition, both parents should give their consent, unless 1 parent is deceased, unknown, incompetent, or not available.
- Can provide documentation of genetic testing results positive for an EDA gene mutation /deletion;
-
As described in Section 3.2 above, subjects must meet one of the following criteria:
- Documented diagnosis of XLHED confirmed via genetic testing;
- Unaffected male controls.
Exclusion Criteria:
- Known hypersensitivity to pilocarpine or pilocarpine-like muscarinic agonists;
- Presence of pacemakers;
- Subjects who are not able or are not willing to comply with the procedures of this protocol;
- Subjects with any major medical problem that will prevent them from participating in this study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01629927
Spain | |
Center for Rare Diseases | |
Burgos, Spain |
Principal Investigator: | Encarna Navarro, MD, PhD | Hospital Universitario Virgen de la Arrixaca |
Responsible Party: | Edimer Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT01629927 |
Other Study ID Numbers: |
ECP-012 |
First Posted: | June 28, 2012 Key Record Dates |
Last Update Posted: | June 28, 2012 |
Last Verified: | June 2012 |
X-linked hypohidrotic ectodermal dysplasia Hypohidrotic ectodermal dysplasia HED XLHED |
Ectodermal Dysplasia Ectodermal Dysplasia 1, Anhidrotic Hyperplasia Pathologic Processes Abnormalities, Multiple Congenital Abnormalities |
Skin Abnormalities Skin Diseases, Genetic Genetic Diseases, Inborn Skin Diseases Genetic Diseases, X-Linked |